Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
AIDS ; 14(18): 2921-7, 2000 Dec 22.
Artigo em Inglês | MEDLINE | ID: mdl-11153673

RESUMO

OBJECTIVES: To evaluate the impact of the modified ACTG 076 zidovudine regimen on the risk for vertical HIV transmission. DESIGN: Observational retrospective evaluation of a prospective cohort. SETTING: Thai Red Cross zidovudine donation program to reduce vertical HIV transmission. PATIENTS: HIV-infected Thai women and their offspring. INTERVENTION: The modified regimen consisted of 500 mg zidovudine daily during pregnancy and 300 mg zidovudine every 3 h during labor, taken orally, and 2 mg/kg zidovudine syrup four times daily for 6 weeks to infants. MAIN OUTCOME MEASURES: Only infants with at least 1 HIV DNA polymerase chain reaction (PCR) result at age > or = 4 weeks were included. HIV infection was defined by having at least one positive PCR at age > or = 4 weeks. The transmission rate was calculated. Characteristics of women who did and did not transmit HIV to infants were compared. RESULTS: A total of 2891 women and their infants participated in the program and 726 infants of 719 women were included in the analysis. Forty-three infants were infected. The overall transmission rate was 6.0% (95% confidence interval, 4.4-8.0). There were no differences in maternal characteristics between transmitters and non-transmitters. The transmission rate in women who started zidovudine before 30 weeks' gestation was not significantly different from that in women who started zidovudine at or after 30 weeks' gestation: 5.7 versus 3.3%, respectively. CONCLUSIONS: This modified zidovudine regimen is effective in reducing vertical transmission in a country with predominant subtype E infection. A donation program for preventing vertical HIV transmission can be implemented in developing countries, as in Thailand.


Assuntos
Infecções por HIV/transmissão , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Cruz Vermelha/economia , Inibidores da Transcriptase Reversa/uso terapêutico , Zidovudina/uso terapêutico , Adulto , Fármacos Anti-HIV/economia , Fármacos Anti-HIV/uso terapêutico , Quimioprevenção , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/prevenção & controle , Humanos , Recém-Nascido , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Complicações Infecciosas na Gravidez/virologia , Avaliação de Programas e Projetos de Saúde , Cruz Vermelha/organização & administração , Inibidores da Transcriptase Reversa/economia , Tailândia , Zidovudina/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...